Literature DB >> 14989127

The role of intraoperative radiotherapy in pancreatic cancer.

Christopher H Crane1, A Sam Beddar, Douglas B Evans.   

Abstract

In single-institution studies, IORT at appropriate doses seems to safely improve local control in patients who have locally advanced pancreatic cancer, compared with historical controls. IORT also has been a component of adjuvant treatment programs that have led to excellent local control in resected patients. When considering the use of IORT, it is essential to have an understanding of the physical characteristics of the electron beam and how it can differ with the use of flat and beveled applicators. Although apparent improvement in local control with the use of IORT seems to have produced some improvement in median survival rates, high rates of distant failure continues to prevent a significant improvement in long-term survival. Because effective local control in patients with unresectable pancreatic cancer is a prerequisite to the development of curative therapies, the development of improved systemic therapies in patients with locally advanced pancreatic cancer will likely make local therapies such as the use of IORT even more important in the future.

Entities:  

Mesh:

Year:  2003        PMID: 14989127     DOI: 10.1016/s1055-3207(03)00090-5

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  8 in total

1.  Benefits of early postoperative jejunal feeding in patients undergoing duodenohemipancreatectomy.

Authors:  Takehiro Okabayashi; Michiya Kobayashi; Isao Nishimori; Tekeki Sugimoto; Toyokazu Akimori; Tsutomu Namikawa; Ken Okamoto; Saburo Onishi; Keijiro Araki
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

Review 2.  Management options in locally advanced pancreatic cancer.

Authors:  Omar Y Mian; Ashwin N Ram; Richard Tuli; Joseph M Herman
Journal:  Curr Oncol Rep       Date:  2014-06       Impact factor: 5.075

3.  Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma.

Authors:  R Krempien; M W Muenter; W Harms; J Debus
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

4.  Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.

Authors:  Daniel W Golden; Caroline J Novak; Bruce D Minsky; Stanley L Liauw
Journal:  Radiat Oncol       Date:  2012-09-13       Impact factor: 3.481

5.  Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

Authors:  R Krempien; M W Muenter; P E Huber; S Nill; H Friess; C Timke; B Didinger; P Buechler; S Heeger; K K Herfarth; A Abdollahi; M W Buchler; J Debus
Journal:  BMC Cancer       Date:  2005-10-11       Impact factor: 4.430

6.  Intraoperative radiotherapy using a mobile electron LINAC: a retroperitoneal sarcoma case.

Authors:  A Sam Beddar; Sunil Krishnan
Journal:  J Appl Clin Med Phys       Date:  2005-08-12       Impact factor: 2.102

Review 7.  Intraoperative radiation therapy (IORT) in pancreatic cancer.

Authors:  Robert Krempien; Falk Roeder
Journal:  Radiat Oncol       Date:  2017-01-10       Impact factor: 3.481

8.  Intraoperative radiation therapy induces immune response activity after pancreatic surgery.

Authors:  Yun Sun Lee; Hyung Sun Kim; Yeona Cho; Ik Jae Lee; Hyo Jung Kim; Da Eun Lee; Hyeon Woong Kang; Joon Seong Park
Journal:  BMC Cancer       Date:  2021-10-12       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.